Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, TRI

Ryght and nmible partner to streamline participant payment data automation and security for clinical trials


LAGUNA BEACH, Calif., April 30, 2024 /PRNewswire/ -- Ryght, a leading enterprise generative AI (GenAI) technology company for healthcare and life sciences, today announced a partnership with nmible, an innovative fintech company that provides reimbursement solutions for clinical trials. The collaboration will enable nmible to integrate Ryght's GenAI capabilities into its platform and use it to automate data processing, enhance security, and optimize workflows for its customers.

nmible will leverage Ryght's advanced GenAI technology, which utilizes various large language models (LLMs) fine-tuned for the sector. The technology will enable nmible to securely and efficiently handle large volumes of data from clinical trial participants without compromising patient privacy or data quality. The partnership will help nmible meet the strict security requirements of trial sponsors and contract research organizations (CROs).

"We've always been excited by the potential of AI to revolutionize clinical trial payment workflows, but data security and privacy concerns have been a significant roadblock," said Jon Anderson, CEO of nmible. "Our partnership with Ryght clears the way for us to innovate on solutions like intelligent data validation, which will dramatically boost the accuracy, efficiency, and speed of our payment processes, while saving valuable time and effort for sponsors, sites and participants. We're thrilled to collaborate with Ryght to introduce cutting-edge AI capabilities that streamline and enhance the clinical trial payment experience, all while upholding the highest data security standards."

"Today, the assurance of patient data security and privacy is more crucial than ever," said Simon Arkell, CEO of Ryght. "Recognizing this imperative, our partnership with nmible signifies a step towards not only ensuring secure access to patient data, but also expediting workflows through automated data processing. By leveraging our GenAI platform, we are transforming data management at scale and instilling confidence among our customers and collaborators. This effort underscores our commitment to improving clinical trial processes, safeguarding patient privacy, and driving efficiency."

Ryght Preview is available to life sciences knowledge workers as a free, secure platform with frictionless sign up. Ryght's copilot library consists of a diverse collection of tools to accelerate information retrieval, document creation, and structuring of vast amounts of complex and unstructured data, taking what might have taken weeks to complete down to days or hours. To inquire about custom building, collaborations, and access to additional copilots, contact Ryght's team of AI experts to discuss Ryght for Enterprise. 

About Ryght:

Ryght is a privately held healthcare technology company with the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the healthcare and life sciences industry. Ryght exists to streamline clinical trials and accelerate workflows for trial sites, sponsors, and life science professionals. The Ryght platform optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams within the compliance and data security standards required by the industry. For more information or to inquire about custom development and collaboration opportunities, please visit www.ryght.ai.

Media contact:

Simon Arkell

Co-Founder/CEO

[email protected]

About nmible:

At nmible we build innovative expense reimbursement software applications to provide equitable access to clinical trials. We reduce the financial burden of participation with fast, flexible cross-border expense and stipend payments, while also supporting hospital sites by reducing the administrative toil of expense processing. We are technology and automation-focused, and our integration capabilities can power all research apps and services with global payment infrastructure. Contact us at [email protected]

Media contact:

John Oxton-King

Head of Product

[email protected]

SOURCE Ryght


These press releases may also interest you

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: